Dividend and Conquer, Medisafe 1 Technologies Doubles (MFTH)

WallSteetPR has covered Medisafe 1 Technologies (OTC: MFTH) before today. Looking at today’s numbers, it is quite clear that people remain afraid of needles. People also fear being accidentally administered drugs intended for another patient, an incorrect dosage, or simple incompetence as well of a host of other problems that hospitals fight each time a patient requires a needle-delivered medication.

The numbers are truly shocking. It is these common mistakes that gave birth to Medisafe 1 Technologies. Medisafe has developed a syringe locking system that requires medical practitioners to scan the needle through a bar code reader in order for the syringe to physically function. In theory, if adopted by hospitals worldwide, its products will save tens of thousands of lives each year.

T0day’s gain, however, was solely based on Medisafe’s intention to offer shareholders a one-time dividend of $0.01 for each share held by investors. Given that Medisafe’s stock began the day at $0.0022, it’s no surprise that this surprise announcement drove the stock up over 120% on the day. It closed at $0.0040, well below the anticipated dividend of $0.01. Trading was heavy with over 1.1 million shares changing hands. It’s difficult to think that the shares will not continue to gain further this week as investors are essentially guaranteed free stock if the price remains below this $0.01 threshold.

This dividend hinges on a $7 million perpetual license sale to an unidentified buyer. Presently, the deal simply awaits the completion of due diligence by this buyer. When the deal was announced on August 30, 2012, Medisafe suggested the deal would be completed within 60 days. Today’s announcement suggested that it would now be completed within the next 30 days.

“Upon the anticipated completion of this non-exclusive perpetual license agreement, we will be extremely pleased to be able to reward our shareholders with this special dividend,” said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. “Similarly, we intend to continue to update our shareholders with further information following the sale’s closing.”

These are clearly the words of a confident executive.

The numbers don’t lie and Medisafe is clearly concerned for your safety with its patented syringes. The following is a list of studies published by various sources in the last two years:

  • 42% of people believed they had personally experienced a medical mistake (NPSF survey).
  • 44,000 to 98,000 deaths annually from medical errors (Institute of Medicine).
  • 225,000 deaths annually from medical errors including 106,000 deaths due to “nonerror adverse events of medications” (Starfield).
  • 180,000 deaths annually from medication errors and adverse reactions (Holland).
  • 7,391 deaths resulted from medication errors (Institute of Medicine).
  • 2.4% to 3.6% of hospital admissions were due to (prescription) medication events (Australian study).

In addition to today’s announcement of the expected dividend, a number of Tweets alerted investors to the situation with Medisafe. California Penny Stock, Penny Stock Zoo, and Stock Market Alerts each took to Twitter multiple times to drum up Medisafe interest.

While no guarantee, Medisafe should continue to rise this week in anticipation of this dividend and the completion of this licensing sale.

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@wallstreetpr.com) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).